AnaptysBio Inc. (ANAB) reported positive results from its Phase 2a trial of ANB020 Tuesday morning. An Eczema Area Severity Index score improvement of 50 percent relative to enrollment baseline was observed in 75 percent of patients after a single dose.
from RTT - Hot Stocks http://ift.tt/2fYxyNh
via IFTTT
No comments:
Post a Comment